| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/17512433.2016.1111137 |
| P698 | PubMed publication ID | 26559084 |
| P50 | author | Yehuda Shoenfeld | Q1515807 |
| Maria-Teresa Arango | Q63759067 | ||
| Shaye Kivity | Q73295123 | ||
| Joab Chapman | Q73298219 | ||
| P2093 | author name string | Britain Baker | |
| P2860 | cites work | Neuropsychiatric lupus: a mosaic of clinical presentations | Q27027588 |
| Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial | Q28304807 | ||
| Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort | Q30873630 | ||
| Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). | Q31129756 | ||
| Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. | Q33415332 | ||
| Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations | Q33574487 | ||
| Neurologic manifestations of systemic lupus erythematosus in children and adults | Q34310715 | ||
| 16/6-idiotype expressing antibodies induce brain inflammation and cognitive impairment in mice: the mosaic of central nervous system involvement in lupus | Q34654431 | ||
| Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis | Q34975939 | ||
| Twenty-year brain magnetic resonance imaging follow-up study in Systemic Lupus Erythematosus: Factors associated with accrual of damage and central nervous system involvement. | Q35548557 | ||
| Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus | Q35555433 | ||
| Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials | Q36302240 | ||
| Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome | Q36720183 | ||
| A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies | Q37020336 | ||
| Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | Q37356697 | ||
| Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers | Q37556128 | ||
| Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients | Q37803363 | ||
| Hydroxychloroquine: from malaria to autoimmunity | Q37827403 | ||
| Mycophenolate mofetil in the treatment of systemic lupus erythematosus | Q37896445 | ||
| Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence | Q37923595 | ||
| Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases | Q38159870 | ||
| Neuropsychiatric systemic lupus erythematosus: tools for the diagnosis | Q38202469 | ||
| Neuropsychiatric systemic lupus erythematosus and cognitive dysfunction: the MRL-lpr mouse strain as a model | Q38245655 | ||
| Cerebellar ataxia in a young patient: A rare path to lupus | Q39068233 | ||
| Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). | Q44316147 | ||
| Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study | Q44915681 | ||
| Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus | Q44996535 | ||
| Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features | Q46809434 | ||
| Successful Treatment of Lupus Cerebrovascular Disease with Mycophenolate Mofetil | Q50437722 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 103-108 | |
| P577 | publication date | 2015-11-11 | |
| P1433 | published in | Expert Review of Clinical Pharmacology | Q15793519 |
| P1476 | title | Pharmacologic management of neuropsychiatric lupus | |
| P478 | volume | 9 |
| Q47243794 | Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu's arteritis. | cites work | P2860 |
Search more.